3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
5004
Neoplasms
4197
Prostatic Neoplasms
2428
Carcinoma, Non-Small-Cell Lung
2265
Colorectal Neoplasms
2053
Lung Neoplasms
1705
Multiple Myeloma
1459
Lymphoma
1405
Leukemia, Myeloid, Acute
1382
Neoplasm Metastasis
1374
Melanoma
1270
Pancreatic Neoplasms
1200
Leukemia
1196
Ovarian Neoplasms
1192
Lymphoma, Non-Hodgkin
1132
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1091
Head and Neck Neoplasms
1056
Leukemia, Lymphocytic, Chronic, B-Cell
994
Lymphoma, Follicular
897
Colonic Neoplasms
895
Brain Neoplasms
876
Stomach Neoplasms
857
Recurrence
853
Carcinoma, Hepatocellular
846
Glioblastoma
841
Lymphoma, Large B-Cell, Diffuse
771
Rectal Neoplasms
759
Uterine Cervical Neoplasms
728
Carcinoma, Renal Cell
705
Hodgkin Disease
698
Interventions
Everolimus
1
Anticonvulsants
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
Tuberous Sclerosis Complex-associated Refractory Seizures
×
Clear all
NCT01713946
2018-11-07
EXIST-3
Novartis
Phase 3
Completed
366 enrolled
38 charts
1 FDA